Results 261 to 270 of about 135,910 (355)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

The simultaneous activation of μ- and δ-opioid receptors by (-)-2<i>S</i>-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model. [PDF]

Curr Res Pharmacol Drug Discov
Fidilio A, Grasso M, Spoto S, Varrasi S, Al-Khrasani M, Caraci F, Parenti C, Pasquinucci L.   +7 more
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Cortical kappa opioid receptors integrate negative affect and sleep disturbance. [PDF]

Transl Psychiatry
Lillo Vizin RC, Ito H, Kopruszinski CM, Ikegami M, Ikegami D, Yue X, Navratilova E, Moutal A, Cowen SL, Porreca F.   +9 more
europepmc   +1 more source

Molecular Mechanisms Regulating Ontogeny of O2- and CO2-Chemosensitivity in Rat Adrenomedullary Chromaffin Cells: Role of Nicotinic ACh and Opioid Receptor Signalling

, 2013
Shaima Salman
openalex   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Opioid receptors: single molecule studies shed light on mechanisms of efficacy. [PDF]

Signal Transduct Target Ther
Krasel C, Bünemann M.
europepmc   +1 more source

Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities

, 2013
Padma Nair, Takashi Yamamoto, Tally M. Largent‐Milnes, Scott Cowell, Vinod Kulkarni, Sharif Moye, Edita Navratilova, Peg Davis, Shou-wu Ma, Todd W. Vanderah, Josephine Lai, Frank Porreca, Victor J. Hruby   +12 more
openalex   +1 more source

Characteristics of methamphetamine‐related deaths in the United Kingdom, 1997–2024

Addiction, EarlyView.
Abstract Background and aims People who use methamphetamine have a standardised mortality ratio 6.8 times greater than the general population, with several countries reporting concerning increases in methamphetamine‐related mortality over the past decade.
Emmert Roberts, Rebecca McKetin, Caroline Copeland   +2 more
wiley   +1 more source

Delta opioid receptors engage multiple signaling cascades to differentially modulate prefrontal GABA release with input and target specificity. [PDF]

Cell Rep
Alexander RPD, Bender KJ.
europepmc   +1 more source